Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 49

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 49
---
 constituted our named executive officers (“NEOs”) for the year ended December 31, 2024:

| MARC STAPLEY                         
 Chief Executive Officer and Director |     | REBECCA CHAMBERS        
 Chief Financial Officer |     | PHILLIP FEBBO                                      
 Chief Scientific Officer and Chief Medical Officer |     | JOHN LEITE                      
 Global Chief Commercial Officer |     | ANNIE MCGUIRE                            
 General Counsel and Chief People Officer |

Executive Summary

### 2024 Business Highlights
In 2024, we continued our strong performance through exceptional execution on the top line and bottom line through disciplined financial and budget management with our growth driven primarily by our Decipher and Afirma products.

#### 46Veracyte2025 Proxy Statement

#### Executive Compensation
Certain financial and operational highlights of 2024 and recent developments include:

| Financial Highlights |     | Total Revenues:$445.8 million (increase of 23% over 2023)                                                                                                                                                                                                                                                                                                                                          
 •Testing Revenue:$419.0 million (increase of 28% over 2023)                                                                                                                                                                                                                                                                                                                                        
 Net Income:$24.1 million (increase of 132% over 2023)                                                                                                                                                                                                                                                                                                                                              
 Cash on Hand:Generated $75.1 million of cash from operations and ended the year with $289.4 million of cash and cash equivalents                                                                                                                                                                                                                                                                   |
| Test Volume          |     | Grew test volume, driven by Decipher and Afirma, to 152,750 in 2024 (increase of 20% over 2023)                                                                                                                                                                                                                                                                                                    
 Our test volume, and revenue, is derived primarily from Decipher and Afirma genomic testing.                                                                                                                                                                                                                                                                                                       
 Our Decipher Prostate test provides actionable information to help physicians and their patients make treatment decisions across the spectrum of localized prostate cancer. As the most validated gene expression prostate test with 85 publications demonstrating the clinical validity and utility of the test, we continued to strengthen the body of evidence in 2024, adding 33 publications. 
 Afirma remains a market leader in thyroid diagnostics and saw positive advancements in 2024. We secured Medicare coverage for Afirma testing of patients with thyroid nodules classified as “Bethesda V,” giving more patients annually access to the test.                                                                                                                                        |
| Other Highlights     |     | Progressed with the launch of our first whole-genome MRD test in Muscle Invasive Bladder Cancer, submitting the technical assessment to MolDx in March of 2025. Adding MRD to our novel